MSD
-
DCGI approves MSD India’s drug KEYTRUDA for triple-negative breast cancer, renal cell carcinoma
KEYTRUDA is an immunotherapy that works with the immune system to help fight cancer cells KEYTRUDA is now approved for…
Read More » -
Aragen expands collaboration with MSD
To provide discovery services to support MSD’s global R&D Hyderabad-headquartered Aragen Life Sciences (Aragen), a leading Contract Research and Development…
Read More » -
Cipla enters into a licensing agreement with MSD
To expand access to investigational oral therapeutic drug for COVID-19 treatment Cipla has signed a non-exclusive licensing agreement with MSD…
Read More » -
MSD ties up with five pharma majors in India for molnupiravir
Molnupiravir is an investigational oral antiviral agent currently being studied in a Phase 3 trial for the treatment of non-hospitalised…
Read More »